Therefore, on the one hand, fraktaline in its soluble form has a beneficial effect on pathology and, therefore, on AD; on the other hand, it’s membrane forms tau phagocytosis because it competes with its binding to the CX3CR1 receptor of microglia. Here, MAPT is linked to Alzheimer disease.